Targeting ovary polypeptide and application thereof

An ovarian and targeted technology, applied in the field of biomedicine, can solve problems such as the advent of drugs, and achieve low risk of immune response activation, avoid side effects, and high selectivity

Pending Publication Date: 2022-06-24
SHENZHEN INST OF ADVANCED TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no good way to overcome age-related senile symptoms. More and more funds are inclined to the research of aging-related diseases, but there is no good drug available yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeting ovary polypeptide and application thereof
  • Targeting ovary polypeptide and application thereof
  • Targeting ovary polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1 Targeting study

[0094] The modified product is selected from the product obtained by fluorescent group modification, or the product obtained by phosphorylation modification, or the product obtained by cyclization modification based on disulfide bond, or the product obtained by biotin labeling modification, or the product obtained by biotin labeling modification. Products modified with photosensitizers, or azide-modified, or PEG-modified, or methylated, or fluorescently quenched, or protein-coupled The product obtained by modification, or the product obtained by modification of small molecule compounds;

[0095] The modified polypeptide Peptide (shown in SEQ ID No. 1) is linked with a fluorophore, so that the polypeptide has fluorescence.

[0096] The mice were divided into four groups, namely Peptide group, PBS group, Flu group and SCR group. The polypeptide Peptide (Peptide group), PBS (PBS group), a single fluorescent material (Flu group) and a scrambled p...

Embodiment 2

[0099] Example 2 Therapeutic experiment on premature ovarian failure

[0100] Establishment of premature ovarian failure model: 8-week-old mice were selected and divided into 4 groups: experimental group CTX group (cyclophosphamide group), experimental group Peptide+CTX group, control group CTRL group and control group Peptide group.

[0101] Mice in the CTX group were injected with 75 mg / kg cyclophosphamide (CTX) on the first day, and then 30 mg / mL cyclophosphamide every other day for 3 weeks.

[0102] The mice in the Peptide+CTX group were injected with cyclophosphamide according to the dose and interval of the mice in the CTX group. Peptide was injected with a dose of 750 nM / g on the day before the first injection of cyclophosphamide. Three weeks.

[0103] Mice in the CTRL group (PBS group) were injected according to the dose and interval of the mice in the CTX group, except that cyclophosphamide was replaced with PBS.

[0104] The mice in the Peptide group used the same ...

Embodiment 3

[0118] Example 3 Therapeutic experiment on improving blood sugar elevation caused by metabolic disorder

[0119] A mouse pathological model of hyperlipidemia-induced polycystic ovary syndrome (PCOS) was established. The specific experimental process was as follows: C57 female mice (21 days old) in the experimental group were injected subcutaneously with DHEA (6 mg / 100 g body weight, 100 μL mice, sesame oil plus 95% ethanol) for 20 consecutive days, high-fat feeding (DHEA+HFD), part of which was injected with Peptide (DHEA+HFD+Peptide) at the same time. The control group was injected with 0.09 mL of sesame oil and 0.01 mL of 95% ethanol every day for 20 days, fed with normal feed, and injected with normal saline (CTRL). After the experiment, the glucose tolerance and insulin tolerance of intraperitoneal injection were detected. Polycystic ovary syndrome is both a reproductive disease and an endocrine disease, mainly because ovarian dysfunction leads to a decrease in estrogen a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a polypeptide and application thereof, and particularly discloses a sequence of the polypeptide as shown in a formula M1-Za-M2, wherein M1 and M2 are each independently a single or multiple amino acid polypeptide segments or do not exist; and Za is His-Val-Gln-X1-Ile-Ser-X2-X3-Gly-X4-Ser-Pro-X5-Ser-X6-Pro-Val-Leu, and the structural formula of Za is shown in the description. The invention also discloses a derivative of the polypeptide. The invention also discloses application of the polypeptide and the derivative in treating or preventing ovarian-derived diseases, metabolic disorders caused by high male and high fat, glycolipid metabolism disorders and hair loss. The polypeptide disclosed by the invention is simple in structure, high in targeting property and excellent in treatment effect.

Description

technical field [0001] The invention discloses an ovary-targeting polypeptide and its derivatives and applications, which belong to the field of biomedicine. Specifically discloses the use of the polypeptide in the preparation of ovary-targeted drugs or detection reagents; and also discloses its derivatives, which are products obtained by modifying the ends or side chains of the polypeptides. Such polypeptide molecules can specifically target ovarian tissue, provide a method for the treatment of ovarian diseases, and can also treat diseases caused by metabolic disorders and aging-related diseases. Background technique [0002] Ovarian diseases mainly include premature ovarian failure, ovarian insufficiency and polycystic ovary syndrome. In recent years, the incidence of ovarian diseases has been on the rise, which leads to loss of fertility and low estrogen status. In addition, the time for fertilization after the oocyte matures is very limited. For example, the optimal t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C12N15/12C07K16/18A61K38/10A61P3/00A61P3/04A61P3/06A61P3/10A61P5/50A61P15/00A61P17/14A61P39/06A61K49/00
CPCC07K7/08C07K16/18A61P15/00A61P3/00A61P39/06A61P17/14A61P3/06A61P3/10A61P5/50A61P3/04A61K49/0017A61K49/0056A61K38/00
Inventor 张键朱雯赵华山杨雅莉葛磊肖天霞
Owner SHENZHEN INST OF ADVANCED TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap